Dubreuil. P P; Brazeau. P P; Moreau. S S; Farmer. C C; Coy. D D; Abribat. T T
In a study using pigs, two modified versions of the growth‑hormone‑releasing factor (GRF‑1‑29) were tested against the natural peptide. The modified peptides worked better, lasted longer in the body, and caused changes in muscle and fat similar to what you’d see with growth hormone. Because pigs are physiologically close to humans, the researchers suggest pigs are a good model for testing new GRF drugs before trying them in people.
Raza. J J; Massoud. A F AF; Hindmarsh. P C PC; Robinson. I C IC; Brook. C G CG
The study shows that the stress hormone CRH can directly block the rise in growth hormone (GH) that normally follows a GH‑releasing hormone (GHRH) shot, and this isn’t because CRH raises ACTH or cortisol. In contrast, giving ACTH or a short‑acting cortisol boost actually makes the GH response bigger. The likely reason is that CRH may trigger somatostatin, which shuts down GH release.
Vittone. J J; Blackman. M R MR; Busby-Whitehead. J J; Tsiao. C C; Stewart. K J KJ; Tobin. J J; Steve...
Giving older men a single nightly shot of the peptide GHRH 1‑29 (2 mg) for six weeks raised their nighttime growth‑hormone spikes and led to small improvements in a few strength tests, but it didn’t change muscle size, body fat, blood sugar, or cholesterol. The study suggests that one‑a‑day dosing is weaker than giving the peptide several times a day.
Wu. D D; Chen. C C; Zhang. J J; Bowers. C Y CY; Clarke. I J IJ
The study shows that two growth‑hormone‑releasing peptides work differently: GHRP‑2 raises cAMP inside pituitary cells like the natural hormone GHRF, while GHRP‑6 triggers GH release without raising cAMP. Both can add to each other's effects, suggesting they hit separate receptors, and all need calcium entry to work. Results differ between sheep and rat cells, hinting that human responses might vary too.
Wu. D D; Chen. C C; Katoh. K K; Zhang. J J; Clarke. I J IJ
In a lab test using sheep pituitary cells, the peptide GHRP‑2 (also called KP 102) boosted growth‑hormone release as strongly as the classic growth‑hormone‑releasing factor (GRF) and was ten times more potent than older GHRP versions. The two peptides added together for an even bigger effect, and GHRP‑2’s action could be blocked by a GRF‑receptor antagonist, showing it works through a different receptor. The response needed calcium entry, but using GHRP‑2 didn’t make the cells less responsive to a later GRF dose.
Boulanger. L L; Lazure. C C; Lefrançois. L L; Gaudreau. P P
The study shows that the natural rat growth‑hormone‑releasing factor peptide (GRF‑1‑29) breaks down quickly in pituitary and hypothalamus tissue, with a half‑life of about 22‑25 minutes, mainly at three specific spots in the chain. This rapid breakdown means the peptide’s effect is short‑lived unless it’s modified to resist those cuts.
Lima. L L; Arce. V V; Tresguerres. J A JA; Devesa. J J
The study shows that activating alpha‑2 adrenergic receptors (with the drug clonidine) can boost the growth‑hormone‑releasing effect of GRF‑1‑29 in rats, but only when the brain's somatostatin (a hormone that blocks growth hormone) is naturally high. When somatostatin is already low, clonidine doesn’t make a difference. This suggests that alpha‑2 adrenergic activity can lift the brake that somatostatin puts on growth hormone release.
Lima. L L; Arce. V V; Diaz. M J MJ; Tresguerres. J A JA; Devesa. J J
The study shows that high cortisol (stress or steroid use) reduces the growth‑hormone boost you get from a GHRH peptide (GRF‑1‑29) by increasing somatostatin release in the brain. Blocking beta‑adrenergic signals with a drug like propranolol, or stimulating alpha‑2 receptors with clonidine, can lift this block and make GH rise higher after a GHRH dose. However, under cortisol excess only the beta‑blocker still works, while clonidine and a cholinergic enhancer (pyridostigmine) lose their effect.
Kumar. S S; Char. H H; Patel. S S; Piemontese. D D; Iqbal. K K; Malick. A W AW; Neugroschel. E E; Be...
The study shows that a mild electric current (iontophoresis) can push a large growth‑hormone‑releasing peptide (GRF‑1‑29 analogue) through skin in a lab test with guinea‑pig skin. Without the current the peptide never gets through, but with it a measurable amount appears on the other side, and the amount delivered goes up with stronger current and more salt in the solution.
The study shows that the natural growth hormone‑releasing factor peptide (GRF‑1‑29) is broken down very quickly in rat blood and liver, disappearing in about 15‑20 minutes. It identifies the exact spots where enzymes cut the peptide, especially a spot that DPP‑IV enzymes target. This means the plain peptide doesn’t stay around long enough to have a strong, lasting effect unless it’s protected or altered.
Deslauriers. N N; Gaudreau. P P; Abribat. T T; Renier. G G; Petitclerc. D D; Brazeau. P P
In rats, the ability of the pituitary gland to release growth hormone (GH) after a dose of GRF‑1‑29 drops noticeably after middle age (around 12 months) and is almost gone in very old rats. This loss is linked to higher levels of somatostatin, a hormone that blocks GH release, and lower overall GH stores in the pituitary.
Goth. M I MI; Lyons. C E CE; Canny. B J BJ; Thorner. M O MO
The study shows that the peptide GRF‑1‑29 (a GHRP) can raise growth hormone (GH) levels by turning on more pituitary cells, but it doesn’t make each cell pump out more hormone. A related brain peptide, PACAP, is even stronger – it both recruits more cells and makes each cell release more GH. All of these effects can be blocked by somatostatin, and the drugs that block GHRP or GHRH only stop their own specific pathway.
Devesa. J J; Diaz. M J MJ; Tresguerres. J A JA; Arce. V V; Lima. L L
In healthy men, drugs that activate alpha‑2 adrenergic receptors (like clonidine) make the GH‑releasing hormone peptide (GRF‑1‑29) cause a bigger growth‑hormone spike, while drugs that block muscarinic cholinergic receptors (like atropine) blunt that spike. Blocking alpha‑2 receptors (with yohimbine) cancels the boost you get from increasing cholinergic activity. This shows the alpha‑2 system is a key driver of GH release, and the cholinergic system works through it.
Kraicer. J J; French. M B MB; Lussier. B T BT; Moor. B C BC; Brazlan. P P
The study shows that the short synthetic version of growth‑hormone‑releasing factor (GRF‑1‑29) works a bit differently than the full‑length natural peptide (GRF‑1‑43). In a lab setting, the short peptide can be less potent, but when tested in a flow‑through system it actually looks more active. However, giving the short peptide once makes the body respond much less (over 50% drop) to any later dose of either peptide, suggesting it can cause quick tolerance.
The study shows that the short form of growth‑release‑factor (GRF‑1‑29) makes rat pituitary cells release growth hormone (GH) within seconds, and this release is tightly linked to a quick burst of calcium leaving the cells. Even when external calcium is removed, GRF‑1‑29 still raises GH, meaning it also taps into calcium stored inside the cells.
Ghigo. E E; Goffi. S S; Mazza. E E; Arvat. E E; Procopio. M M; Bellone. J J; Müller. E E EE; Ca...
In healthy adults, giving a second dose of GHRH about two hours after the first leads to a much smaller growth hormone (GH) spike, while kids don’t show this drop. Adding a cholinesterase blocker (pyridostigmine) that helped adults doesn’t boost the GH response in children either.
Felix. A M AM; Heimer. E P EP; Wang. C T CT; Lambros. T J TJ; Fournier. A A; Mowles. T F TF; Maines....
Scientists created a ring‑shaped version of the growth‑hormone‑releasing peptide GRF‑1‑29 that still works and can be even more powerful when certain building blocks are swapped. The cyclic shape keeps the peptide in a helical form in water, which likely helps it stay active.
In rats, a slow‑release injection of the somatostatin‑like drug RC‑160 kept growth‑hormone spikes down for at least four days after a growth‑hormone‑releasing signal and also lowered high prolactin levels. The treated rats gained less weight than untreated ones.
Grossman. A A; Savage. M O MO; Lytras. N N; Preece. M A MA; Sueiras-Diaz. J J; Coy. D H DH; Rees. L...
The study shows that the short GHRH peptide GRF‑1‑29 works just as well as the longer version for triggering growth hormone release in healthy people, but giving more of it mainly stretches out the release rather than making the peak higher. In growth‑hormone‑deficient patients, a few still respond to the peptide, especially if they aren't already on long‑term GH therapy. Priming with extra doses doesn’t boost the effect.
Robberecht. P P; Gillard. M M; Waelbroeck. M M; Camus. J C JC; De Neef. P P; Christophe. J J
In older rats, the ability of the peptide GRF‑1‑29 to boost a key enzyme (adenylate cyclase) in the pituitary drops by about half, even though the enzyme itself and other signaling pathways stay the same. This suggests that aging reduces the number or function of GRF receptors, so the same dose of the peptide may be less effective in older animals.